The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Cancer
Breast Cancer

For Patient
For Medical Professional
Download
Print

Basic Details

Gender

Female

Age

≥18 Years

Healthy Volunteers

Sponsor Genentech, Inc.

Phase Phase 1

Study Identifier NCT03916744, GO40987, 2018-003798-85

This clinical trial was done to study a new medicine called, “giredestrant”, also known as “GDC-9545”, for the treatment of patients with “ER+ positive breast cancer”. This study was done to find out whether giredestrant was effective in slowing down ER+ breast cancer cell growth in patients. Researchers also wanted to find out if it was safe and if patients could tolerate this medicine. Seventy-five patients with HER+ breast cancer signed up for the study at 15 study centers across five countries.

This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Results Disclaimer

What you can do next

Save the study number

To find this study again later, copy and save the study number:

Talk to a doctor or nurse

To see if this study is a good fit, talk to your doctor or nurse you trust.

Together, you can look at the For Medical Professional tab and look into your medical history.

Reach out for more info

Some medical centers in this study offer a contact line. Click "Find participating medical centers" in the map below.

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

Basic Details

Sponsor Genentech, Inc.

Phase Phase 1

Trial Identifier NCT03916744, GO40987, 2018-003798-85

Condition Breast Cancer

Official Title A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Study Summary

This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

Eligibility Criteria

Gender

Female

Age

≥18 Years

Healthy Volunteers

Inclusion Criteria

Ability to comply with the study protocol, in the investigator's judgment
Histologically confirmed invasive breast carcinoma, with all of the following characteristics: Primary tumor greater than or equal to (≥)1.5 centimeters (cm) in largest diameter by ultrasound; Stage I-III operable breast cancer; Documentation confirming the absence of distant metastasis (M0) as determined by institutional practice.
ER-positive tumor and HER2-negative breast cancer as per local laboratory testing
Postmenopausal status
Breast cancer eligible for primary surgery
Submission of a representative tumor tissue specimen
Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (≤)1
Adequate organ function

Exclusion Criteria

Diagnosis of inflammatory breast cancer
Diagnosis of bilateral breast cancer
Concurrent use of hormone replacement therapies
Previous systemic or local treatment for the primary breast cancer currently under investigation
Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study entry
Current treatment with any systemic anti-cancer therapies
Major surgery within 4 weeks prior to enrollment
Radiation therapy within 2 weeks prior to enrollment
Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
Known HIV infection
Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
History of allergy to giredestrant or any of its excipients
Any condition requiring anti-coagulants, such as warfarin, heparin, or thrombolytic drugs
History of documented hemorrhagic diathesis or coagulopathy
History or presence of symptomatic bradycardia or sick sinus syndrome
Baseline heart rate ≤55 beats per minute (bpm) prior to enrollment
History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
QT interval corrected through use of Fridericia's formula (QTcF) >470 milliseconds demonstrated by at least two ECGs >30 minutes apart
History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease, clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome
Current treatment with medications that are well known to prolong the QT interval
History or presence of uncontrolled hypothyroidism
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Results Disclaimer

The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

Basic Details

What you can do next

What is Clinical Research?

Basic Details

Study Summary

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Contact Genentech

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

Basic Details

What you can do next

Find participating medical centers and current study status in each of them

Explore related studies

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com